Request Free Sample
×
Industry Developments
The China Radiopharmaceuticals Market has seen significant developments recently, particularly with companies such as Jiangxi Aibo Pharmaceutical and Hunan Shunxin Pharmaceutical expanding their product lines, catering to the growing demand for targeted therapies. In September 2023, Beijing HaGP Pharma announced a collaboration with Tsinghua University to enhance the development of radioligand therapies, indicating a trend towards academic-industry partnerships. Additionally, Changchun Biontech Inc. has been advancing its research into diagnostic and therapeutic radioisotopes, reflecting broader efforts within the industry to integrate innovative solutions into healthcare systems. Notably, in August 2023, Jiangsu Pacific Pharmaceuticals acquired a smaller firm focusing on the production of radiopharmaceuticals, bolstering its market position. The Chinese government continues to support the radiopharmaceutical sector by increasing investments and fostering collaborations, which has led to an overall market valuation growth of over 7% over the last two years. Companies like Nanjing Kingfriend Biochemical Pharmaceutical and Shenzhen New Industries Biomedical Engineering have played essential roles in this growth, contributing to advancements in cancer treatment protocols within the region.
China Radiopharmaceuticals Market Report Scope
Report Scope
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 0.49(USD Billion) |
| MARKET SIZE 2024 | 0.53(USD Billion) |
| MARKET SIZE 2035 | 1.28(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.18% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Jiangxi Aibo Pharmaceutical, Tsinghua University, Hunan Shunxin Pharmaceutical, Changchun Biontech Inc., Nanjing Kingfriend Biochemical Pharmaceutical, Beijing HaGP Pharma, Sichuan Ya'an Xiehe Pharmaceutical, China National Nuclear Corporation, Hubei Hualan Biological Engineering, Shanghai United Imaging Healthcare, Jiangsu Pacific Pharmaceuticals, Shenzhen New Industries Biomedical Engineering, Hainan Shuangcheng Pharmaceutical, Guangzhou CMER Eye Care Holdings |
| SEGMENTS COVERED | Type, Application |
| KEY MARKET OPPORTUNITIES | Increased cancer prevalence, Growing diagnostic imaging demand, Expansion of production facilities, Advancements in radiopharmaceutical technologies, Favorable regulatory environment |
| KEY MARKET DYNAMICS | Growing elderly population, Increasing cancer prevalence, Advancements in imaging technologies, Supportive regulatory environment, Expanding healthcare infrastructure |
| COUNTRIES COVERED | China |
Leave a Comment
FAQs
What is the estimated market value of the China Radiopharmaceuticals Market in 2024?
The China Radiopharmaceuticals Market is expected to be valued at 0.53 USD Billion in 2024.
What is the projected market size for the China Radiopharmaceuticals Market by 2035?
By 2035, the market is projected to reach a value of 1.28 USD Billion.
What is the expected compound annual growth rate (CAGR) for the China Radiopharmaceuticals Market from 2025 to 2035?
The expected CAGR for the China Radiopharmaceuticals Market is 8.18% from 2025 to 2035.
Which company holds a significant market share in the China Radiopharmaceuticals Market?
Major players in the market include Jiangxi Aibo Pharmaceutical, Tsinghua University, and Hunan Shunxin Pharmaceutical.
What is the market value of the Diagnostic segment in the China Radiopharmaceuticals Market for 2024?
The Diagnostic segment is valued at 0.25 USD Billion in 2024.
What is the expected market size for the Therapeutic segment in 2035?
The Therapeutic segment is expected to reach a value of 0.62 USD Billion by 2035.
What are the key application areas driving growth in the China Radiopharmaceuticals Market?
Key application areas include diagnostic imaging and therapeutic treatments.
How will regional factors impact the market growth for radiopharmaceuticals in China?
Regional factors such as increasing healthcare investments and demand for advanced imaging will significantly drive market growth.
What challenges could affect the growth of the China Radiopharmaceuticals Market?
Challenges include regulatory hurdles and the need for substantial R&D investments.
What are the emerging trends in the China Radiopharmaceuticals Market?
Emerging trends include advancements in radiopharmaceutical development and increasing focus on personalized medicine.
Download Free Sample
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
Case Study
Aerospace & Defense